JP2023541011A5 - - Google Patents
Info
- Publication number
- JP2023541011A5 JP2023541011A5 JP2023515183A JP2023515183A JP2023541011A5 JP 2023541011 A5 JP2023541011 A5 JP 2023541011A5 JP 2023515183 A JP2023515183 A JP 2023515183A JP 2023515183 A JP2023515183 A JP 2023515183A JP 2023541011 A5 JP2023541011 A5 JP 2023541011A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- group
- cmet
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063075702P | 2020-09-08 | 2020-09-08 | |
| US63/075,702 | 2020-09-08 | ||
| PCT/US2021/049310 WO2022055893A1 (en) | 2020-09-08 | 2021-09-07 | Pharmaceutical combination and tumor treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023541011A JP2023541011A (ja) | 2023-09-27 |
| JP2023541011A5 true JP2023541011A5 (https=) | 2024-09-17 |
Family
ID=80629827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515183A Pending JP2023541011A (ja) | 2020-09-08 | 2021-09-07 | 医薬組み合わせおよび腫瘍治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250017921A1 (https=) |
| EP (1) | EP4210704A4 (https=) |
| JP (1) | JP2023541011A (https=) |
| AU (1) | AU2021339579A1 (https=) |
| CA (1) | CA3191363A1 (https=) |
| IL (1) | IL300952A (https=) |
| MX (1) | MX2023002757A (https=) |
| WO (1) | WO2022055893A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024542831A (ja) * | 2021-12-06 | 2024-11-15 | アイディアヤ バイオサイエンシーズ，インコーポレイティド | Ｐｋｃ阻害剤及びｃ－ｍｅｔ阻害剤を含む併用療法 |
| EP4577212A1 (en) * | 2022-08-26 | 2025-07-02 | Ideaya Biosciences, Inc. | Methods of treating uveal melanoma |
| KR20260005936A (ko) * | 2023-04-21 | 2026-01-12 | 아이디어야 바이오사이언시스 인코포레이티드 | 간에만 전이된 포도막 흑색종의 치료 방법 |
| WO2025240628A1 (en) * | 2024-05-15 | 2025-11-20 | Ideaya Biosciences, Inc. | Processes for preparing a pkc inhibitor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010121175A1 (en) | 2009-04-17 | 2010-10-21 | Rush University Medical Center | Combination targeted therapy for lung cancer |
| EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| US20140222443A1 (en) * | 2011-06-07 | 2014-08-07 | Kathleen Danenberg | Molecular profiling for cancer |
| SG11201402004YA (en) * | 2011-11-14 | 2014-05-29 | Cephalon Inc | Uracil derivatives as axl and c-met kinase inhibitors |
| WO2014174478A1 (en) | 2013-04-26 | 2014-10-30 | Novartis Ag | Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor |
| JO3589B1 (ar) * | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| WO2019053595A1 (en) | 2017-09-12 | 2019-03-21 | Novartis Ag | INHIBITORS OF PROTEIN KINASE C FOR THE TREATMENT OF CHOROIDAL MELLANOMA |
| SI3908282T1 (sl) | 2019-01-07 | 2026-01-30 | Ideaya Biosciences, Inc. | Zdravljenje raka z genetskimi mutacijami gnaq ali gna11 z zaviralci protein kinaze c |
-
2021
- 2021-09-07 WO PCT/US2021/049310 patent/WO2022055893A1/en not_active Ceased
- 2021-09-07 JP JP2023515183A patent/JP2023541011A/ja active Pending
- 2021-09-07 AU AU2021339579A patent/AU2021339579A1/en active Pending
- 2021-09-07 MX MX2023002757A patent/MX2023002757A/es unknown
- 2021-09-07 US US18/043,298 patent/US20250017921A1/en active Pending
- 2021-09-07 IL IL300952A patent/IL300952A/en unknown
- 2021-09-07 EP EP21867451.3A patent/EP4210704A4/en active Pending
- 2021-09-07 CA CA3191363A patent/CA3191363A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023541011A5 (https=) | ||
| Dong et al. | MET-targeted therapies and clinical outcomes: a systematic literature review | |
| US20230210852A1 (en) | Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9 | |
| Ilson et al. | A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus | |
| Sheng et al. | GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis | |
| ES2529790T3 (es) | Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB | |
| ES2874875T3 (es) | Procedimiento de tratamiento de adenocarcinoma de pulmón | |
| EP2715366B1 (en) | Biomarkers for hedgehog inhibitor therapy | |
| TW202136252A (zh) | 化合物及其用途 | |
| JP6761798B2 (ja) | タンパク質キナーゼ阻害剤に対する感受性予測用組成物、キット、及び方法 | |
| JP2018526324A (ja) | がんの診断および処置の方法 | |
| Ha et al. | Decreased selenium-binding protein 1 mRNA expression is associated with poor prognosis in renal cell carcinoma | |
| García-Alfonso et al. | Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology | |
| Bircan et al. | EGFR and KRAS mutations in Turkish non-small cell lung cancer patients: a pilot study | |
| Andea et al. | Merkel cell carcinoma: correlation of KIT expression with survival and evaluation of KIT gene mutational status | |
| AU2026200456A1 (en) | Treatment of canine cancers | |
| ES3054788T3 (en) | Treatment of cancer having gnaq or gna11 genetic mutations with protein kinase c inhibitors | |
| JP6465790B2 (ja) | Ｍａｐｋシグナル伝達経路を阻害する化合物に対する応答性を予測する方法 | |
| Wang et al. | Clinicopathologic features and molecular spectrum of spindle cell and sclerosing rhabdomyosarcomas in the head and neck region | |
| KR20230087445A (ko) | Aml의 치료 요법 및 rara 작용제, 저메틸화제, 및 bcl-2 억제제의 용도 | |
| WO2005075681A1 (ja) | 抗癌剤に対する癌細胞の感受性を検定する方法 | |
| Gao et al. | Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals | |
| JP7747459B2 (ja) | Ｆｇｆｒ阻害薬に対する感受性の判定方法 | |
| Jaramillo et al. | Gastrointestinal stromal tumors (GISTs): role of CD 117 and PDGFRA Golgi-like staining pattern in the recognition of mutational status | |
| Bang et al. | Recent trends (1991-2010) of metastatic skin cancers in Korea |